特刊“药物固体形态：从晶体结构到制剂”
Special Issue "Pharmaceutical Solid Forms: From Crystal Structure to Formulation".
作者信息
Espeau Philippe
机构信息
Unit of Chemical and Biological Technologies for Health (UTCBS), CNRS, INSERM, Université Paris Cité, 75006 Paris, France.
出版信息
Pharmaceutics. 2025 Feb 28;17(3):312. doi: 10.3390/pharmaceutics17030312.
Abstract
This Special Issue aims to highlight the interest of characterizing the structural aspects of an API before its formulation, as much work is required between the discovery of a molecule with a therapeutic effect and its formulation [...].
摘要
本期特刊旨在强调在药物活性成分（API）制剂前对其结构特征进行表征的重要性，因为从发现具有治疗作用的分子到其制剂之间需要开展大量工作[...]。
相似文献
1
Special Issue "Pharmaceutical Solid Forms: From Crystal Structure to Formulation".特刊“药物固体形态：从晶体结构到制剂”
Pharmaceutics. 2025 Feb 28;17(3):312. doi: 10.3390/pharmaceutics17030312.
2
Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.喷雾包封作为基于药物的室温离子液体的配方策略：利用药物-聚合物不混溶性来实现固体剂型的加工。
Mol Pharm. 2020 Sep 8;17(9):3412-3424. doi: 10.1021/acs.molpharmaceut.0c00467. Epub 2020 Aug 27.
3
Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.药物研发中原料药晶型的选择与控制——策略与流程
Curr Opin Drug Discov Devel. 2008 Nov;11(6):771-7.
4
The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?晶体形式在制药领域的相关性：达摩克利斯之剑还是创新工具？
Int J Mol Sci. 2022 Aug 12;23(16):9013. doi: 10.3390/ijms23169013.
5
Selective detection of active pharmaceutical ingredients in tablet formulations using solid-state NMR spectroscopy.利用固态 NMR 光谱法选择性检测片剂制剂中的活性药物成分。
Solid State Nucl Magn Reson. 2020 Apr;106:101651. doi: 10.1016/j.ssnmr.2020.101651. Epub 2020 Jan 28.
6
Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.共无定形活性药物成分-小分子混合物：增强溶解和口服生物利用度的共晶选择考虑因素。
J Pharm Sci. 2018 Jan;107(1):5-17. doi: 10.1016/j.xphs.2017.09.024. Epub 2017 Oct 5.
7
API co-crystals - Trends in CMC-related aspects of pharmaceutical development beyond solubility.API 共晶——药物开发中与 CMC 相关方面的超越溶解度的趋势。
Drug Discov Today. 2023 May;28(5):103527. doi: 10.1016/j.drudis.2023.103527. Epub 2023 Feb 14.
8
[Formulation and special investigations of innovative intraoral solid dosage forms.].[创新口腔内固体剂型的配方及特殊研究。]
Acta Pharm Hung. 2016;86(3):99-111.
9
An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.在药物研发早期如何处理原料药中非晶形部分的一个例子：SAR114137——一种成功的方法。
Eur J Pharm Biopharm. 2014 Apr;86(3):337-50. doi: 10.1016/j.ejpb.2013.09.015. Epub 2013 Sep 26.
10
Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.将活性药物成分的固体形态选择和颗粒工程整合到药物产品设计中。
J Pharm Pharmacol. 2015 Jun;67(6):782-802. doi: 10.1111/jphp.12375. Epub 2015 Feb 10.
本文引用的文献
1
Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.药物溶剂化物、水合物和无定形形式：特别关注共晶。
Adv Drug Deliv Rev. 2017 Aug 1;117:25-46. doi: 10.1016/j.addr.2017.03.002. Epub 2017 Mar 22.
2
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs.多晶型对难溶性药物生物利用度和稳定性的影响。
Molecules. 2015 Oct 15;20(10):18759-76. doi: 10.3390/molecules201018759.
3
Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.水溶解度的晶体和无定形药物：测量的挑战。
Pharm Dev Technol. 2011 Jun;16(3):187-200. doi: 10.3109/10837451003774377. Epub 2010 Apr 30.
4
Ritonavir: an extraordinary example of conformational polymorphism.利托那韦：构象多态性的一个非凡例子。
Pharm Res. 2001 Jun;18(6):859-66. doi: 10.1023/a:1011052932607.
Zotero 插件